Clinical often non-steroidal anti-inflammatory drugs and slow-acting anti-rheumatic drugs combined application is because non-steroidal anti-inflammatory drugs mainly play a symptomatic role in antipyretic, analgesic treatment, while slow-acting anti-rheumatic drugs mainly play a role in controlling and slowing down the progress of the disease course, the two drugs play different roles. Non-steroidal anti-inflammatory drugs and slow-acting anti-rheumatic drugs are commonly used in the clinical treatment of rheumatoid arthritis and other autoimmune diseases. Rheumatoid arthritis and other patients often experience joint pain, joint swelling, morning stiffness and other symptoms, and non-steroidal anti-inflammatory drugs, such as diclofenac and etoricoxib, can play a symptomatic therapeutic effect of antipyretic, analgesic, but can not slow down or stop the aggravation of the disease. Slow-acting anti-rheumatic drugs include traditional synthetic drugs and biosynthetic drugs, representing methotrexate, leflunomide, adalimumab, etc., which can control and slow down the progression of the disease to varying degrees. However, slow-acting anti-rheumatic drugs are relatively slow to take effect, and non-steroidal anti-inflammatory drugs (NSAIDs) should be used for anti-inflammatory and analgesic treatment before anti-rheumatic drugs take effect. The drugs should be used under the supervision of a physician. It is recommended that patients who need to use non-steroidal anti-inflammatory drugs and slow-acting anti-rheumatic drugs for treatment go to the rheumatology and immunology departments of regular hospitals for consultation, and do not take medication on their own.